Clinical trials: Gastro-Intestinal Disorders
Iron Deficiency Anemia, Constipation
Investigating the Effects of Iron on the Gastrointestinal Tract
Many patients that are prescribed iron report gastrointestinal side effects. This research project aims to investigate if the gastrointestinal symptoms of taking iron supplementation are related to changes in gases produced by…
- Trial name
- GI-iron (NCT04253652)
- Testing
- Fasted breath samples, IBS-SSS, Daily diary
- Where
- United Kingdom
- Volunteers
- 155 people
- Sponsor
- The Functional Gut Clinic
Oncology, Metabolic Disease
Nutritional Safety and Metabolic Benefits of Oncometabolic Surgery for Obese Gastric Cancer Patients
The metabolic effect of oncometabolic surgery (long limb Roux-en Y reconstruction) for early gastric cancer patients has been revealed in a few pilot studies.
- Conditions
- Oncology, Metabolic Disease, Gastric Cancer
- Trial name
- ONCOMETAB (NCT03067012)
- Testing
- Oncometabolic reconstruction
- Volunteers
- 20 people
- Sponsor
- Seoul National University Bundang Hospital
Gastro Esophageal Reflux
Near Focus NBI-Driven Artificial Intelligence for the Diagnosis of Gastro-Oesophageal Reflux Disease
Gastro-oesophageal reflux disease (GORD) is a chronic condition with symptoms arising secondary to the reflux of stomach contents (Vakil et al., 2006).
- Trial name
- NCT04268719
- Testing
- wireless pH capsule recording
- Where
- United Kingdom
- Volunteers
- 76 people
- Sponsor
- King's College Hospital NHS Trust
Stomach Ulcer
Healing Effects of Rebamipide and Omeprazole in Helicobacter Pylori-positive Gastric Ulcer After Eradication Therapy
The purpose of this study is to evaluate the ulcer healing efficacy of rebamipide in comparison with omeprazole in Helicobacter pylori-positive gastric ulcer after eradication therapy.
- Trial name
- NCT00272467
- Testing
- Rebamipide, Omeprazole
- Where
- 7 sites in China, South Korea
- Volunteers
- 132 people
- Sponsor
- Korea Otsuka International Asia Arab
Gastro-esophageal Reflux Disease
Nociceptors, Neurotrophic Factors and Cytokine Expression in Gastroesophageal Reflux Disease
Transient receptor potential vanilloid-1 (TRPV1) receptor and proteinase-activated receptor 2 (PAR2) have been implicated in the mechanism of acid induced inflammation in gastroesophageal reflux disease (GERD).
- Trial name
- NCT02114216
- Testing
- endoscopic mucosal biopsy
- Where
- South Korea
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Seoul National University Bundang Hospital
Ovarian Neoplasms, Colorectal Neoplasms
An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation
Doctors will take some tissue from the tissue removed during surgery in order to study how the blood vessels of the tumor respond to radiation therapy.
- Conditions
- Ovarian Neoplasms, Colorectal Neoplasms, Melanoma, Small Cell Lung Cancer
- Trial name
- NCT00132704
- Testing
- Ionizing radiation (IR) therapy, Ionizing radiation (IR)
- Where
- United States
- Volunteers
- 149 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Gastroesophageal Reflux
The Use of Proton Pump Inhibitor for the Treatment of Non-erosive Gastro-oesophageal Reflux Disease in Chinese Population
The purpose of this study is to evaluate the efficacy of proton pump inhibitor for the treatment of non-erosive reflux disease (NERD) in Chinese population.
- Trial name
- NCT00516971
- Testing
- Esomeprazole 20mg once daily
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hospital Authority, Hong Kong
Solid Tumor, Gastric Cancer
A Phase I Trial of CCT303-406 in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
This clinical study is to investigate the safety and tolerability of CCT303-406 CAR modified autologous T cells (CCT303-406) in subjects with relapsed or refractory stage IV metastatic HER2-positive solid tumors.
- Conditions
- Solid Tumor, Gastric Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT04511871
- Testing
- CCT303-406
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai PerHum Therapeutics Co., Ltd.
Colorectal Cancer, Non-Small Cell Lung Cancer
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
This study will test the safety and effectiveness of a drug called IM-1617 in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with…
- Conditions
- Colorectal Cancer, Non-Small Cell Lung Cancer, Breast Cancer, Esophageal Cancer
- Trial name
- NCT07578571
- Testing
- IM-1617
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- Immunome, Inc.
Advanced Cancers
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
The goal of this clinical research study is to find the highest tolerable doses of the combinations of lenalidomide and other drugs that can be given to patients with advanced cancer.
- Trial name
- NCT01183663
- Testing
- Lenalidomide, Bevacizumab, Sorafenib
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- M.D. Anderson Cancer Center
Paralytic Stroke, Cough
Diaphragmatic Function in Stroke Patients.
This study attempts to elucidate whether stroke patients with dysphagia have reduced diaphragm movement during voluntary coughing, and also during deep inspiration and expiration than stroke patients without dysphagia.
- Trial name
- NCT01637649
- Where
- South Korea
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- The Catholic University of Korea
Pain, Cancer
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy
GIC-1001 is a novel, orally-administered, colonic analgesic drug developed as an alternative to i.v. sedation during full colonoscopy.
- Conditions
- Pain, Cancer, Colonic Diseases
- Trial name
- NCT01926444
- Testing
- GIC-1001
- Where
- 15 sites in United States, Canada
- Volunteers
- 308 people
- Sponsor
- gicare Pharma Inc.
Swallowing Disorders, Dysphagia
The Objective is to Respond to Patients' Needs in the Field of Larynx Replacement
Supplement pharyngolaryngeal deficient functions by insertion of a prosthesis with valves in order to allow tracheotomy closing (when applicable) and / or to allow restoration of god swallowing capacity.
- Conditions
- Swallowing Disorders, Dysphagia, Laryngeal Neoplasms
- Trial name
- NCT00576134
- Testing
- Implantation of intralaryngeal prosthesis with a new double valve system, allowing tracheotomy closing
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Strasbourg, France
Breast Cancer, Bladder Cancer
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
The basic premise of this research proposal is to determine whether there is any significant association between germline polymorphisms and cancers of colon, bladder, breast, testicular, prostate, ovaries, kidney, lung, lymphoid…
- Conditions
- Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer
- Trial name
- NCT00579514
- Testing
- PCR/PCR/LDR Strategy
- Where
- United States
- Volunteers
- 21,081 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Type 1 Diabetes, Celiac Disease
Combined Antibody Screening for Celiac and Diabetes Evaluation
The CASCADE Study (Combined Antibody Screening for Celiac and Diabetes Evaluation) is an observational study whose primary goal is to show that population-based screening for advanced prediction of type 1 diabetes (T1D) and…
- Trial name
- CASCADE (NCT04677699)
- Testing
- Combined Risk Score
- Where
- United States
- Volunteers
- 64,410 people, healthy volunteers welcome
- Sponsor
- Pacific Northwest Research Institute
Non Small Cell Lung Cancer, Esophageal Cancer
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.
- Conditions
- Non Small Cell Lung Cancer, Esophageal Cancer, Small Cell Lung Cancer, Nasopharyngeal Cancer
- Trial name
- NCT05983432
- Testing
- BL-B01D1
- Where
- 37 sites in United States, France and 3 more
- Volunteers
- 540 people
- Sponsor
- SystImmune Inc.
Roux-en-y Anastomosis Site, Marginal Ulcer
Marginal Ulcer Healing With Low-Thermal Argon Plasma Endoscopic Treatment
The objective of the study is to investigate the treatment of marginal ulcers with Low Thermal plasma in an endoscopic setting. By a treatment of the ulcerated areas with argon plasma with low power settings (~ 1 W) we…
- Conditions
- Roux-en-y Anastomosis Site, Marginal Ulcer, Marginal Ulcer (Peptic) or Erosion, Ulcer
- Trial name
- AMULET (NCT06543316)
- Testing
- Low Thermal Plasma (LTP) Treatment, Standard of Care Ulcer Treatment (typically PPI Administration)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Christopher C. Thompson, MD, MSc
Acute Myelogenous Leukemia, Ovarian Cancer
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.
- Conditions
- Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer
- Trial name
- NCT03761914
- Testing
- galinpepimut-S, pembrolizumab, Montanide
- Where
- 12 sites in United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Sellas Life Sciences Group
Dysphagia, Aspiration
PEG by Introducer Method Via EG Scan
Percutaneous endoscopic gastrostomy(PEG) by introducer method has been proven to be safe and easy to perform. However, it is limited by its need to be performed in an endoscopy unit. E.G.
- Conditions
- Dysphagia, Aspiration, Esophageal Stenosis
- Trial name
- NCT02183207
- Testing
- Percutaneous Endoscopic Gastrostomy
- Where
- South Korea
- Volunteers
- 24 people
- Sponsor
- The Catholic University of Korea
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors.
- Conditions
- Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT04389632
- Testing
- sigvotatug vedotin, pembrolizumab, cisplatin
- Where
- 158 sites in United States, France and 5 more
- Volunteers
- 1,006 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.